In:
Journal of the National Comprehensive Cancer Network, Harborside Press, LLC, Vol. 21, No. 4 ( 2023-04), p. 423-429
Abstract:
HER2 is overexpressed in approximately 20% of esophagogastric cancer (EGC) cases. The addition of the anti-HER2 antibody, trastuzumab, to chemotherapy in 2010 was the first targeted treatment to demonstrate an improvement in survival. The aggressive nature and heterogeneous biology of EGC have posed a particular challenge and resulted in numerous negative trials without a change in standard of care for more than a decade. However, with the incorporation of dual HER2 and PD-1 blockade as well as the advent of a new, potent antibody–drug conjugate, trastuzumab deruxtecan, there have been 2 new FDA approvals for this patient population within the past 2 years. Consequently, the management and landscape of HER2-positive EGC is rapidly changing and increasingly optimistic.
Type of Medium:
Online Resource
ISSN:
1540-1405
,
1540-1413
DOI:
10.6004/jnccn.2023.7010
Language:
Unknown
Publisher:
Harborside Press, LLC
Publication Date:
2023
Permalink